Phase I study of temozolomide in paediatric patients with advanced cancer

British Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 652-661

  Estlin, E J ^a,c   Lashford, L ^a   Ablett, S ^a   Price, L ^a   Gowing, R ^a   Gholkar, A ^a   Kohler, J ^a   Lewis, I J ^a   Morland, B ^a   Pinkerton, C R ^a   Stevens, M C G ^a   Mott, M ^a   Stevens, R ^a   Newell, D R ^a   Walker, D ^a   Dicks Mireaux, C ^a   McDowell, H ^a   Reidenberg, P ^b   Statkevich, P ^b   Marco, A ^b   Batra, V ^b   Dugan, M ^b   Pearson, A D J ^a   more..

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Children; Phase I study; SCH 52365; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; ATAXIA; BONE MARROW SUPPRESSION; BRAIN STEM TUMOR; CATHETER INFECTION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; EPISTASIS; FATIGUE; FEMALE; GLIOMA; HEADACHE; HEMATOMA; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PETECHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 17644443014     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.555     Document Type: Article

References (21)

1. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M and Stevens MFG (1995) Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913
2. Brada M, Moore S, Judson I, Batra VJ, Quartey P and Dugan M (1995) A Phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc Am Soc Clin Oncol 14: 484
3. Catapano CV, Broggini M, Erba E, Ponti M, Mariani L, Citti L and D'Incalci M (1987) In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukaemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884-4889
4. 6-alkylguanine DNA methyltransferase in human normal and tumour tissue from brain, lung, and ovary. Cancer Res 51: 4131-4134
5. CPMP Working Party on the efficacy of Medicinal Products (1990) European Community Commission notes for guidance: Good Clinical Practice for trials of Medicinal Products in the European Community. J Pharmacol Toxicol 67: 361-372
6. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM and Suman VJ (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3: 1093-1100
7. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 15: 178
8. Gundersen S, Aamdal S and Fodstad O (1987) Mitozolomide (NSC35451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br J Cancer 55: 1249-1250
9. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC and Simon RM (1994) A comparison of two Phase I trial designs. Stat Med 13: 1799-1806
10. Liu L, Markovitch S and Gerson SL (1996). Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-Bis(2-chloroethy)nitrosourea. Cancer Res 56: 5375-5379
11. Marsoni S, Ungerleider R, Hurson S and Hammershaimb L (1985) Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 69: 1263-1269
12. Mosteller RD (1987) Simplified calculation of body-surface area. New Engl J Med 317: 1098
13. Newlands ES, Blackridge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quaterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC (1992). Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
14. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P and Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942
15. Pearson ADJ, Price L, Hofer C, Lashford L, Lewis IJ, Mott M, Newell DR, Pinkerton CR, Stevens R, Stevens R and Windebank K (1994) Phase I study of continuous intravenous infusion of low dose thiotepa in children. Med Paediatr Oncol 23: 270
16. Reidenberg P, Villalona M, Eckhardt G, Rodriguez G, Burris H, Von Hoff D, Statkevich P, Batra V, Dugan M and Eckhardt J (1996) Phase I clinical and pharmacokinetic study of temozolomide in advanced cancer patients stratified by extent of prior therapy. Proc 9th NCI/EORTC Symp New Drugs Cancer Ther 7: 344
17. Schering-Plough Research Institute, Department of Drug Metabolism and Pharmacokinetics (1996) A Phase I study of SCH 52365 in adult patients with advanced cancer. Appendix B-1: Pharmacokinetics of SCH 52365 (temozolomide). Schering-Plough Research Institute, Report Number 193-114-01.
18. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW and Slack JA (1987) Antitumour activity and Pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
19. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1103
20. WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. World Health Organization: Geneva
21. Woll PJ, Crowther D, Johnson PWM, Soukop M, Harper PG, Harris M, Brampton MH and ES Newlands (1995) Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72: 183-184